Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention |
Kim, Jin-hyun
(College of Nursing, Seoul National University)
Shin, Sang-Jin (School of Public Health, Seoul National University) Kim, Eun-Ju (School of Public Health, Seoul National University) Lee, Young-Hee (School of Public Health, Seoul National University) |
1 | Topol, E. J., Califf, R. M., Weisman, H. F., Ellis, S. G., Tcheng, J. E., Worley, S., Ivanhoe, R., George, B. S., Fintel, D., Weston, M., et al. : Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343, 8902 (1994) |
2 | 박우석, 정명호, 김남호, 안영근, 배열, 길광채, 조정관, 박종춘, 강정채 : 고위험군 환자의 Abciximab(ReoPro)을 사용하며 성공 적으로 시행한 관상동맥 중재술 1예. 대한중환자의학회지 13, (1998) |
3 | Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J., Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C., Cabot, C. F., Anderson, K. M., Weisman, H. F. and Topol, E. J. : Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial.Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 99, 15 (1999) |
4 | Kereiakes, D. J., Obenchain, R. L., Barber, B. L., Smith, A., McDonald, M., Broderick, T. M., Runyon, J. P., Shimshak, T. M., Schneider, J. F., Hattemer, C. R., Roth, E. M., Whang, D. D., Cocks, D. and Abbottsmith, C. W. : Abciximab provides cost-effective survival advantage in high-volume interventional practice. Am. Heart. J. 140, 4 (2000) |
5 | 김원, 정명호, 홍영준, 이승현, 박우석, 김주한, 김인수, 최명자, 안영근, 조정관, 박종춘, 조동련, 김훈, 강정채 : 혈소판 당단백 IIb/IIIa 수용체 차단제(Abciximab: ReoPro)부착 관상동맥 스텐트의 장기 임상결과. 대한내과학회지 65, 6 (2003) |
6 | Stone, G. W., Grines, C. L., Cox, D. A., Garcia, E., Tcheng, J. E., Griffin, J. J., Guagliumi, G., Stuckey, T., Turco, M., Carroll, J. D., Rutherford, B. D. and Lansky, A. J. : Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. The New England Journal of Medicine 346, 13 (2002) DOI ScienceOn |
7 | Hillegass, W. B., Newman, A. R. and Raco, D. L. : Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics 19, 1 (2001) |
8 | The EPIC Investigation: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The New England Journal of Medicine 330, 14 (1994) |
9 | Aristides, M., Gliksman, M., Rajan, N. and Davey, P. : Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Heart 79, 1 (1998) |
10 | Tenaglia, A. N., Fortin, D. F., Califf, R. M., Frid, D. J., Nelson, C. L., Gardner, L., Miller, M., Navetta, F. I., Smith, J. E., Tcheng, J. E., et al. : Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J. Am. Coll. Cardiol. 24, 4 (1994) |
11 | Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P., Anderson, K. M. and Califf, R. M. : Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/ IIIa Inhibition for Prevention of Ischemic Complication. Jama 278, 6 (1997) |
12 | 정해억, 승기배, 장정원, 김용주, 임상현, 김태균, 장기욱, 임효영, 정욱성, 김종진, 채장성, 김재형, 홍순조, 최규보 : 급성 심근경색증에 대한 일차 관상동맥중재술 중 투여한 압시씨맵(Abciximab) 의 관상동맥 혈류개선효과에 대한 분석-교정 TIMI Frame계산법을 이용하여. Korean Circulation 30, 7 (2000) |
13 | Oh, P. I., Cohen, E. A., Mittmann, N. and Seung, S. J. : The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both? Can. J. Clin. Pharmacol. 11, 2 (2004) |
14 | Lincoff, A. M., Popma, J. J., Ellis, S. G., Hacker, J. A. and Topol, E. J. : Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J. Am. Coll. Cardiol. 19, 5 (1992) |
15 | The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. The New England Journal of Medicine 336, 24 (1997) |
16 | Ellis, S. G., Roubin, G. S., King, S. B., 3rd, Douglas, J. S., Jr., Weintraub, W. S., Thomas, R. G. and Cox, W. R. : Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 77, 2 (1988) DOI PUBMED ScienceOn |
17 | 권운정, 이태홍, 이병희, 김동현, 김학진, 김석, 김창원, 추기석, 문태용 : 두개강 내 동맥 스텐트 삽입시 발생한 급성 스텐트 내 혈전에 대한 Abciximab 동맥 내 주입치료의 유용성. 대한영상의학회지 51, (2004) |
18 | Young, J. J. and Kereiakes, D. J. : Abciximab: cost-effective survival advantage in clinical trials and clinical practice. Am. Heart. J. 140, 6 Suppl (2000) |
19 | The CAPTURE Study: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349, 9063 (1997) |
20 | Weintraub, W. S., Mahoney, E. M., Zhang, Z., Chu, H., Hutton, J., Buxton, M., Booth, J., Nugara, F., Stables, R. H., Dooley, P., Collinson, J., Stuteville, M., Delahunty, N., Wright, A., Flather, M. D. and Cock, E. De : One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart 90, (2004) |
21 | 김원, 정명호, 홍영준, 박형욱, 이민구, 정선영, 김인수, 김계훈, 윤경호, 강동구, 홍서나, 임상엽, 이상현, 이연상, 김주한, 안영근, 조정관, 박종춘, 김훈, 조동련, 강정채 : 급성 심근경색증 환자에 게 혈소판 당단백 IIb/IIIa 수용체 차단제(AbciximabL ReoPro) 부착 관상동맥 스텐트의 장기임상결과. Korean Circulation 34, 11 (2004) |
22 | Califf, R. M. : Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses? Stat. Med. 21, 19 (2002) |
23 | Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J. M., Morice, M. C., Maillard, L., Pansieri, M., Choussat, R. and Pinton, P. : Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England Journal of Medicine 344, 25 (2001) |
24 | McCollam, P. L., Foster, D. A. and Riesmeyer, J. S. : Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Health Syst. Pharm. 60, 12 (2003) PUBMED |
25 | Lincoff, A. M., Califf, R. M., Moliterno, D. J., Ellis, S. G., Ducas, J., Kramer, J. H., Kleiman, N. S., Cohen, E. A., Booth, J. E., Sapp, S. K., Cabot, C. F. and Topol, E. J. : Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. The New England Journal of Medicine 341, 5 (1999) |
26 | Brener, S. J., Barr, L. A., Burchenal, J. E., Katz, S., George, B. S., Jones, A. A., Cohen, E. D., Gainey, P. C., White, H. J., Cheek, H. B., Moses, J. W., Moliterno, D. J., Effron, M. B. and Topol, E. J.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98, 8 (1998) |
27 | Stinnett, A. A., Mittleman, M. A., Weinstein, M. C., Karen, M. K., Cohen, D. J., Williams, L. W., Goldman, P. A., Staiger, D. O., Hunink, M. G. M., Tsevat, J., Tosteson, A. N. A., Goldman, L. : The Cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In: Gold, M. R., Stegel, J. E., Russell, L. B., Weinstein, M. C., eds. Cost- Effectiveness in Health and Medicine. New york: Oxford University Press, 349 (1996) |
28 | Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J., Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C. F., Anderson, K. M. and Califf, R. M. : Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 354, 9195 (1999) DOI PUBMED ScienceOn |